Anzeige
Mehr »
Login
Montag, 01.07.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
Mit voller Kasse und frischer Ware kommt jetzt wieder ordentlich Schwung in diese Aktie!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
214 Leser
Artikel bewerten:
(1)

ArisGlobal: Top 5 Global Biotech Company Goes Live with LifeSphere® MultiVigilance and Reporting & Analytics Solution

  • The top-tier life sciences company will standardize its Safety operations on the cloud-powered technology platform, LifeSphere, which is propelling life sciences GenAI use cases.
  • The company will use LifeSphere MultiVigilance and Reporting & Analytics Solution to process some 600,000 adverse event cases annually.

BOSTON, June 27, 2024 /PRNewswire/ -- ArisGlobal, a technology company at the forefront of life sciences and creator of LifeSphere®, today announced one of the world's largest biotech companies is live on LifeSphere® MultiVigilance and Reporting & Analytics Solution.

ArisGlobal Logo

The company, which processes more than 600,000 adverse event cases annually and operates across all modern therapy areas and medical devices, sees the consolidation of core Safety activities from legacy on-premise systems to LifeSphere as a powerful means of streamlining the processing of high volumes of incoming data to deliver world-class patient safety.

As a member of the Life Sciences Generative AI Council, the biotech innovator is particularly keen to leverage the capabilities of LifeSphere NavaX, ArisGlobal's next-generation cognitive computing engine. The organization is working closely with ArisGlobal to further leverage advanced technology including GenAI to revolutionize global pharmacovigilance (PV) processes.

Commenting on this latest prestigious win, Rajendra Hattarki, SVP, Global Head of Consulting at ArisGlobal, said: "That yet another top-tier global life sciences brand is actively capitalizing on all that LifeSphere makes possible in automating key Safety processes, is further confirmation of the rise in aggressive, important automation and AI initiatives and priorities, for which LifeSphere is a core solution - today. We are thrilled to have met this milestone with such a fantastic organization and anticipate more success together in the future."

Ann-Marie Orange, CIO and Global Head of R&D, added: "LifeSphere is a tangible solution for pharma, enabling the implementation of AI and GenAI solutions right now. In this latest go-live, our platform is delivering on-demand access to the very latest advanced automation capabilities, unprecedented scalability, and effortless regulatory compliance in each process across this powerful platform. Lifesphere as a SaaS solution frees up pharma's vital resources previously managing internal systems and infrastructure. Standardizing on LifeSphere substantially enhances Safety processes and their efficient delivery, allowing pharma organizations to focus on their core business."

About ArisGlobal
ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, is transforming the way today's most successful life sciences companies develop breakthroughs and bring new products to market. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan, and China. For more updates, follow ArisGlobal on LinkedIn or visit www.arisglobal.com.

Logo - https://mma.prnewswire.com/media/1510670/ArisGlobal_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/top-5-global-biotech-company-goes-live-with-lifesphere-multivigilance-and-reporting--analytics-solution-302183333.html

© 2024 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.